Chinese PLA General Hospital: Leukemia trials

The registry lists 14 Leukemia studies with Chinese PLA General Hospital as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 10Phase 2 10Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCTRecruitingNCT04764513Phase 1/2
• Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT05659992Phase 2
• Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive ChemotherapyStatus unknownNCT04541277Phase 2
• Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic LeukemiaStatus unknownNCT04012879Phase 1
• A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory LeukemiaStatus unknownNCT03463928Phase 1
• A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT03398967Phase 1/2
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Status unknownNCT03185494Phase 1/2
• A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and LymphomaStatus unknownNCT03166878Phase 1/2
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20CompletedNCT03097770Phase 1/2
• Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell TransplantationStatus unknownNCT02784561Phase 4
• Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33Status unknownNCT01864902Phase 1/2
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19Status unknownNCT01864889Not applicable
• Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell TransplantationStatus unknownNCT01758367Phase 1/2
• Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to ChemotherapyStatus unknownNCT01735604Phase 1/2